Skip to main content
AZTA
NASDAQ Life Sciences

Azenta Guides FY27 Revenue to $648-$660M as Organic Growth Stalls at 2%

Tom Rudovsky · Reported by PR Newswire
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$39.99
Mkt Cap
$1.773B
52W Low
$15.93
52W High
$46.41
52W Position info
151% above low
Off High info
14% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

AZTA has more than doubled off its 52-week low of $15.93.

Summary

Azenta closed fiscal 2026 with Q4 revenue of $167 million, up 5% reported but only 2% organic, and full-year revenue of $622 million on the same 5%/2% split. The headline problem is profitability: FY26 adjusted EBITDA fell to $58.3 million (9.4% margin) from $66.3 million (11.2%), and GAAP results carried a $149 million non-cash goodwill impairment taken in Q2, driving a full-year diluted loss from continuing operations of $3.50 per share. Q4 EPS came in at 16c, while Q4 adjusted diluted EPS of $0.28 did beat last year's $0.21, and gross margin improved 60 bps to 46.0%, so the second half did show better momentum under interim CEO Dr. Martin Madaus. FY27 guidance calls for revenue of $648-$660 million, 3-5% organic growth, and 200-250 bps of adjusted EBITDA margin expansion — but that margin number includes roughly 100 bps of dilution from the Elegen license and SynPlexity acquisition closed in late October, so underlying improvement is thinner than the headline range suggests. Free cash flow is guided to improve about 25% off FY26's $27 million, a low base. The setup follows a turbulent stretch: CEO John Marotta resigned in August, the Multiomics restructuring closed three North American labs in October, and material weaknesses in internal controls remain outstanding from the Q3 10-Q. The earnings call is November 11 at 8:30 a.m. ET.

At the time of this announcement, AZTA was trading at $39.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $15.93 to $46.41. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.


Price Chart

Share this article

Copied!

AZTA - Latest Insights

AZTA
Nov 10, 2026, 5:44 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $44.20
Real-time Price: $44.20 info
Change: $0 (0%) info
Market Cap: $1.773B info
AZTA
Oct 30, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $39.87
Real-time Price: $44.20 info
Change: +$4.33 (+11%) info
Market Cap: $1.773B info
AZTA
Oct 07, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $40.04
Real-time Price: $44.20 info
Change: +$4.16 (+10%) info
Market Cap: $1.773B info
AZTA
Aug 24, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.90
Real-time Price: $44.20 info
Change: +$7.30 (+20%) info
Market Cap: $1.773B info
AZTA
Aug 06, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.74
Real-time Price: $44.20 info
Change: +$13.46 (+44%) info
Market Cap: $1.773B info